Role of p53 in the progression of gastric cancer

Oncotarget

Volumn 5, Issue 23, 2014, Pages 12016-12026

  Busuttil, Rita A ^a,b   Zapparoli, Giada V ^a,c   Haupt, Sue ^a,b   Fennell, Christina ^a   Wong, Stephen Q ^a   Pang, Jia Min B ^a,b   Takeno, Elena A ^a   Mitchell, Catherine ^a   Di Costanzo, Natasha ^a   Fox, Stephen ^a,b   Haupt, Ygal ^a,b,c,d   Dobrovic, Alexander ^a,b,c   Boussioutas, Alex ^a,b,e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Gastric cancer; Intestinal metaplasia; Mdmx; Mutation; TP53

Indexed keywords

PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MELTING POINT; MUTATIONAL ANALYSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; SOMATIC MUTATION; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH MUCOSA; TUMOR SUPPRESSOR GENE; UPREGULATION; BIOSYNTHESIS; DISEASE COURSE; DNA MUTATIONAL ANALYSIS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PRECANCER; REAL TIME POLYMERASE CHAIN REACTION; STOMACH TUMOR;

BIOMARKERS, TUMOR; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NUCLEAR PROTEINS; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84920019404     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2434     Document Type: Article

References (38)

1. Parkin DM. International variation. Oncogene. 2004; 23(38):6329-6340.
2. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108.
3. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988; 48(13):3554-3560.
4. Boussioutas A, Li H, Liu J, Waring P, Lade S, Holloway AJ, Taupin D, Gorringe K, Haviv I, Desmond PV and Bowtell DD. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res. 2003; 63(10):2569-2577.
5. Rubio CA, Hirota T, Itabashi M, Mandai K, Yanagisawa A, Kitagawa T, Sugano H and Kato Y. Extended intestinal metaplasia. A survey of 1392 gastrectomies from dwellers of the Pacific basin. Anticancer Res. 2004; 24(5B):3185-3192.
6. Jass JR and Filipe MI. A variant of intestinal metaplasia associated with gastric carcinoma: a histochemical study. Histopathology. 1979; 3(3):191-199.
7. Filipe MI, Potet F, Bogomoletz WV, Dawson PA, Fabiani B, Chauveinc P, Fenzy A, Gazzard B, Goldfain D and Zeegen R. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut. 1985; 26(12):1319-1326.
8. Kang KP, Lee HS, Kim N, Kang HM, Park YS, Lee DH, Choe G, Kim JS, Jung HC and Song IS. Role of intestinal metaplasia subtyping in the risk of gastric cancer in Korea. J Gastroenterol Hepatol. 2008.
9. Busuttil RA and Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis. J Gastroenterol Hepatol. 2009; 24(2):193-201.
10. Fenoglio-Preiser CM, Wang J, Stemmermann GN and Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat. 2003; 21(3):258-270.
11. Shiao YH, Palli D, Caporaso NE, Alvord WG, Amorosi A, Nesi G, Saieva C, Masala G, Fraumeni JF, Jr. and Rice JM. Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers. Cancer Epidemiol Biomarkers Prev. 2000; 9(6):631-633.
12. Gleeson CM, Sloan JM, McManus DT, Maxwell P, Arthur K, McGuigan JA, Ritchie AJ and Russell SE. Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer. 1998; 77(2):277-286.
13. Tolbert D, Fenoglio-Preiser C, Noffsinger A, De Voe G, MacDonald J, Benedetti J and Stemmermann GN. The relation of p53 gene mutations to gastric cancer subsite and phenotype. Cancer Causes Control. 1999; 10(3):227-231.
14. Anagnostopoulos GK, Stefanou D, Arkoumani E, Karagiannis J, Paraskeva K, Chalkley L, Habilomati E, Tsianos E and Agnantis NJ. Immunohistochemical expression of cell-cycle proteins in gastric precancerous lesions. J Gastroenterol Hepatol. 2008; 23(4):626-631.
15. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-767.
16. Wade M, Li YC and Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013; 13(2):83-96.
17. Ye Y, Li X, Yang J, Miao S, Wang S, Chen Y, Xia X, Wu X, Zhang J, Zhou Y, He S, Tan Y, Qiang F, Li G, Roe OD and Zhou J. MDM2 is a useful prognostic biomarker for resectable gastric cancer. Cancer Sci. 2013; 104(5):590-598.
18. Gonzalez CA, Sanz-Anquela JM, Gisbert JP and Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer. 2013; 133(5):1023-1032.
19. Gunther T, Schneider-Stock R, Hackel C, Kasper HU, Pross M, Hackelsberger A, Lippert H and Roessner A. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol. 2000; 13(6):621-626.
20. Filipe MI, Munoz N, Matko I, Kato I, Pompe-Kirn V, Jutersek A, Teuchmann S, Benz M and Prijon T. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer. 1994; 57(3):324-329.
21. Lukashchuk N and Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol. 2007; 27(23):8284-8295.
22. Wu MS, Shun CT, Lee WC, Chen CJ, Wang HP, Lee WJ, Sheu JC and Lin JT. Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer. 1998; 78(7):971-973.
23. Shiao YH, Rugge M, Correa P, Lehmann HP and Scheer WD. p53 alteration in gastric precancerous lesions. The American journal of pathology. 1994; 144(3):511-517.
24. Gomyo Y, Osaki M, Kaibara N and Ito H. Numerical aberration and point mutation of p53 gene in human gastric intestinal metaplasia and well-differentiated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Int J Cancer. 1996; 66(5):594-599.
25. Brito MJ, Williams GT, Thompson H and Filipe MI. Expression of p53 in early (T1) gastric carcinoma and precancerous adjacent mucosa. Gut. 1994; 35(12):1697-1700.
26. Cesar AC, Borim AA, Caetano A, Cury PM and Silva AE. Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer. Cancer genetics and cytogenetics. 2004; 153(2):127-132.
27. Silva TC, Leal MF, Calcagno DQ, de Souza CR, Khayat AS, dos Santos NP, Montenegro RC, Rabenhorst SH, Nascimento MQ, Assumpcao PP, de Arruda Cardoso Smith M and Burbano RR. hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions. BMC gastroenterology. 2012; 12:85.
28. Sud R, Wells D, Talbot IC and Delhanty JD. Genetic alterations in gastric cancers from British patients. Cancer genetics and cytogenetics. 2001; 126(2):111-119.
29. Haupt Y, Maya R, Kazaz A and Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387(6630):296-299.
30. Stad R, Ramos YF, Little N, Grivell S, Attema J, van Der Eb AJ and Jochemsen AG. Hdmx stabilizes Mdm2 and p53. J Biol Chem. 2000; 275(36):28039-28044.
31. Martins CP, Brown-Swigart L and Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006; 127(7):1323-1334.
32. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445(7128):661-665.
33. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C and Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 445(7128):656-660.
34. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, et al. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006; 444(7115):61-66.
35. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012.
36. Mitchell G, Ballinger ML, Wong S, Hewitt C, James P, Young MA, Cipponi A, Pang T, Goode DL, Dobrovic A and Thomas DM. High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS One. 2013; 8(7):e69026.
37. Acosta D, Adelman J, Affolder T, Akimoto T, Albrow MG, Ambrose D, Amerio S, Amidei D, Anastassov A, Anikeev K, Annovi A, Antos J, Aoki M, Apollinari G, Arisawa T, Arguin JF, et al. Measurement of the W(+)W(-) production cross section in pp collisions at square root[s]=1.96 TeV using dilepton events. Phys Rev Lett. 2005; 94(21):211801.
38. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D and Brenton JD. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010; 221(1):49-56.